Patient's Knowledge on Their Anticoagulating and Anti Platelet Treatment St Joseph's Hospital)

• Sponsor: Groupe Hospitalier Paris Saint Joseph (Other)
• Overall Status: Completed
• CT.gov ID: NCT03304977
• Collaborator: (none)
• Enrollment: 100
• Location: 1
• Actual Duration (Months): 4.8
• Patients Per Site Per Month: 20.8

Study Details

Study Description

Brief Summary

Oral antigoagulant are used more than 60 years in thrombotic diseases. Even they are indispensable, the haemorragic risk is high.That's why it's the main reason of hospitalization for iatrogeny.The complication's reasons are mainly linked to errors of drug intake, drugs interaction and the lack of understanding the treatment.Moreover, the antiplatelet agglutening treatment is frequently added to anticoagulant treatment.This increases the haemorragic risk.Different means were used to minimize the risk , like INR follow up.

The purpose of the study is to evaluate smartphone use to follow the patients'treatment.

Condition or Disease	Intervention/Treatment	Phase
Coagulation Disorder	Other: questionnaire via smartphone	N/A

Detailed Description

Two questionnaire via smartphone with 15 days gap.

Study Design

• Study Type: Interventional
• Actual Enrollment: 100 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Current Situation of the Patient's Knowledge on Their Anticoagulating and Anti Platelet Treatment in GHPSJ (St Joseph's Hospital)
• Actual Study Start Date: Jun 6, 2016
• Actual Primary Completion Date: Jul 31, 2016
• Actual Study Completion Date: Oct 30, 2016

Outcome Measures

Primary Outcome Measures

1. smartphone use level [15 days]

   evaluation of the interest of patient to use their smartphone in the purpose to follow their anticoagulant treatment

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• patient under ant-thrombotic treatment

• hospitalized in vascular medecine service

Exclusion Criteria:

• refusing the participation

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Groupe Hospitalier Paris Saint Joseph	Paris	Ile-de-France	France	75014

Sponsors and Collaborators

• Groupe Hospitalier Paris Saint Joseph

Investigators

• Study Director: Pascal PRIOLLET, MD, GHPSJ

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Groupe Hospitalier Paris Saint Joseph
• ClinicalTrials.gov Identifier: NCT03304977
• Other Study ID Numbers: CACHACA
• First Posted: Oct 9, 2017
• Last Update Posted: Oct 9, 2017
• Last Verified: Sep 1, 2017

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Hemostatic Disorders; Blood Coagulation Disorders

Study Results

No Results Posted as of Oct 9, 2017